linsitinib
AssetAlso ASP-7487, OSI-906, OSI-906AA
Inhibits IGF-1 and insulin receptor tyrosine kinases, blocking downstream signaling.
- Stage
- Phase 3
- Modality
- Small molecule
- Target
- Insulin/IGF-1 signalling
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Thyroid eye disease
Phase 3, businesswire.com, 9 Oct 2026
In the full profile
- Targets and what it contains3
- Owner and partners1
- Evidence for its targets3
- Competitors12
- Aging relevance1
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.